Stay updated on Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial

Sign up to get notified when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:38:26.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a shift in the study details related to a randomized trial for patients with metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer, focusing on the efficacy of Ribociclib after progression on CDK4/6 inhibition in patients switching anti-estrogen therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:55.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' with additional details on examples of these criteria, such as a person's general health condition or prior treatments.
    Difference
    56%
    Check dated 2024-05-22T21:25:56.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:32:23.000Z thumbnail image

Stay in the know with updates to Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.